Active Trials

Total Trials

Organizations

Events

Taiwan

Medical Only (Private)

Reimbursed Care Access

Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled‑drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C‑X, ayahuasca preparations) have no authorized medical use outside approved clinical research and are treated as illicit. Ketamine is an accepted medical anesthetic and is used clinically (and appears in addiction / forensic policing statistics), but non‑medical possession and diversion are criminalized; dedicated esketamine (Spravato®) regulatory status in Taiwan is not documented in public TFDA approvals as of Feb 20, 2026. [https://www.mohw.gov.tw/cp-3163-28284-1.html|Ministry of Health and Welfare MOHW overview] [https://mohw.gov.tw/fp-16-21181-1.html|MOHW: new psychoactive & controlled substances advisory].

Read Full Access Guide View Active Trials

Clinical Trials in Taiwan

CompletedPhase IV

Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression

Randomised, double-blind, parallel-group trial (n=12 actual) testing IV low-dose ketamine 0.5 mg/kg versus active placebo (midazolam 0.045 mg/kg) in adolescents (13–19) with treatment-resistant depression.

Started: March 15, 2022
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: NCT05045378

CompletedPhase IV

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Open-label single-group long-term extension (n=183) assessing long-term safety and tolerability of intranasal esketamine plus SSRI/SNRI in participants with treatment-resistant major depressive disorder who completed prior esketamine study.

Started: April 26, 2021
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT04829318

CompletedPhase III

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

This Phase III interventional trial (n=676) evaluated flexibly dosed esketamine nasal spray versus quetiapine XR, both with a continuing SSRI/SNRI, in participants with treatment-resistant major depressive disorder.

Started: August 21, 2020
Type: interventional
Blinding: none
Randomized: Yes
Registry ID: NCT04338321

Unknown statusPhase NA

Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide

Double-blind, randomised, parallel-group trial (n=48) comparing a single 0.5 mg/kg ketamine infusion versus active placebo midazolam 0.045 mg/kg in adults with treatment-resistant depression to assess antidepressant and antisuicidal effects.

Started: September 10, 2018
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: NCT03666390

CompletedPhase III

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I)

Double-blind, randomised, placebo-controlled Phase III trial (n=226) testing intranasal esketamine 84 mg twice weekly for 4 weeks plus standard of care versus intranasal placebo plus standard of care for rapid reduction of MDD symptoms including suicidal ideation in adults at imminent suicide risk.

Started: June 9, 2017
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: NCT03039192

CompletedPhase III

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Open-label, long-term extension Phase III safety study (n≈1148) of esketamine nasal spray (flexible 28–84 mg dosing) in participants with treatment-resistant depression, induction twice weekly for 4 weeks then individualised maintenance.

Started: June 9, 2016
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT02782104

Taiwan

Reimbursed Care Access

Clinical Trials in Taiwan

Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Research Events

Company

Product

Legal

Taiwan

Reimbursed Care Access

Clinical Trials in Taiwan

Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/​Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Research Events

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)